Martin S. Rhee

2.8k total citations · 1 hit paper
53 papers, 1.5k citations indexed

About

Martin S. Rhee is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Martin S. Rhee has authored 53 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Infectious Diseases, 40 papers in Virology and 22 papers in Emergency Medicine. Recurrent topics in Martin S. Rhee's work include HIV/AIDS drug development and treatment (49 papers), HIV Research and Treatment (40 papers) and HIV-related health complications and treatments (22 papers). Martin S. Rhee is often cited by papers focused on HIV/AIDS drug development and treatment (49 papers), HIV Research and Treatment (40 papers) and HIV-related health complications and treatments (22 papers). Martin S. Rhee collaborates with scholars based in United States, United Kingdom and Italy. Martin S. Rhee's co-authors include Christian Callebaut, Edwin DeJesus, Peter Ruane, Hadas Dvory‐Sobol, Nicolas Margot, Andrew Cheng, Lijie Zhong, Joel E. Gallant, Javier Szwarcberg and Srini Ramanathan and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Martin S. Rhee

48 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

2022 164 citations Sorana Segal‐Maurer, Edwin DeJesus et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin S. Rhee United States	21	1.3k	1000	387	298	139	53	1.5k
Marshall W. Fordyce United States	16	1.5k 1.1×	955 1.0×	500 1.3×	443 1.5×	233 1.7×	30	1.8k
Javier O Morales-Ramirez United States	11	1.8k 1.4×	1.5k 1.5×	383 1.0×	231 0.8×	87 0.6×	13	1.9k
Keith A. Pappa United States	16	1.3k 1.0×	986 1.0×	394 1.0×	215 0.7×	77 0.6×	36	1.5k
Brian Woodfall United States	20	1.8k 1.3×	1.4k 1.4×	208 0.5×	363 1.2×	129 0.9×	29	1.9k
Cynthia Brinson United States	18	1.3k 1.0×	1.0k 1.0×	449 1.2×	333 1.1×	118 0.8×	36	1.5k
Cindy Vavro United States	15	1.4k 1.0×	1.1k 1.1×	308 0.8×	284 1.0×	72 0.5×	26	1.5k
Hal Martin United States	21	1.6k 1.2×	1.2k 1.2×	838 2.2×	252 0.8×	135 1.0×	44	1.8k
Erin Quirk United States	19	1.6k 1.2×	1.2k 1.2×	605 1.6×	277 0.9×	126 0.9×	42	1.8k
Andrew Mulato United States	22	1.6k 1.2×	1.2k 1.2×	174 0.4×	586 2.0×	232 1.7×	33	2.1k
Akil Jackson United Kingdom	20	686 0.5×	525 0.5×	228 0.6×	197 0.7×	59 0.4×	52	888

Countries citing papers authored by Martin S. Rhee

Since Specialization

Citations

This map shows the geographic impact of Martin S. Rhee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin S. Rhee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin S. Rhee more than expected).

Fields of papers citing papers by Martin S. Rhee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin S. Rhee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin S. Rhee. The network helps show where Martin S. Rhee may publish in the future.

Co-authorship network of co-authors of Martin S. Rhee

This figure shows the co-authorship network connecting the top 25 collaborators of Martin S. Rhee. A scholar is included among the top collaborators of Martin S. Rhee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin S. Rhee. Martin S. Rhee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hagins, Debbie, Mezgebe Berhe, Gordon Crofoot, et al.. (2025). Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV. AIDS. 40(3). 302–311.

Subramanian, Raju, William Rowe, Michael Graupe, et al.. (2024). Pharmacokinetics, Disposition, and Biotransformation of [14C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion. Clinical Pharmacokinetics. 63(2). 241–253. 8 indexed citations

Ogbuagu, Onyema, Jean‐Michel Molina, Ploenchan Chetchotisakd, et al.. (2024). Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial. Clinical Infectious Diseases. 80(3). 566–574. 14 indexed citations

Kumar, Princy, Deborah Goldstein, Richard L. Hengel, et al.. (2023). 1581. Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80. Open Forum Infectious Diseases. 10(Supplement_2). 2 indexed citations

Margot, Nicolas, et al.. (2023). Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA. Antiviral Therapy. 28(6). 211946514–211946514. 17 indexed citations

Ogbuagu, Onyema, Edwin DeJesus, Mezgebe Berhe, et al.. (2023). 1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results. Open Forum Infectious Diseases. 10(Supplement_2). 4 indexed citations

Álvarez, Elena, Lucy Campbell, Willard Tinago, et al.. (2022). The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study. Antiviral Therapy. 27(4). 201820658–201820658. 2 indexed citations

Gupta, Samir K., Mezgebe Berhe, Gordon Crofoot, et al.. (2022). Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. The Lancet HIV. 10(1). e15–e23. 65 indexed citations

Margot, Nicolas, Laurie A. VanderVeen, Renee R. Ram, et al.. (2022). Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study. Journal of Antimicrobial Chemotherapy. 77(4). 989–995. 38 indexed citations

10.

Gaur, Aditya H., Pope Kosalaraksa, Natella Rakhmanina, et al.. (2017). Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. The Lancet Child & Adolescent Health. 1(1). 27–34. 22 indexed citations

11.

Gallant, Joel E., Eric S. Daar, François Raffi, et al.. (2016). Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. The Lancet HIV. 3(4). e158–e165. 127 indexed citations

12.

Sáez‐Llorens, Xavier, Elizabeth Castaño, Mobeen H. Rathore, et al.. (2014). A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1–infected Children With Virologic Suppression. The Pediatric Infectious Disease Journal. 34(4). 376–382. 15 indexed citations

13.

McDonald, Cheryl, Claudia Martorell, Moti Ramgopal, et al.. (2014). Cobicistat-Boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment. HIV Clinical Trials. 15(6). 269–273. 12 indexed citations

14.

Gazzard, Brian, Pierre Marie Girard, Giovanni Di Perri, et al.. (2014). Long‐term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV‐1‐infected treatment‐naïve subjects ≥50 years. Journal of the International AIDS Society. 17(4S3). 19767–19767. 2 indexed citations

15.

Gallant, Joel E., Ellen Koenig, Jaime Andrade‐Villanueva, et al.. (2013). Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results. The Journal of Infectious Diseases. 208(1). 32–39. 84 indexed citations

16.

Post, Frank, Jonathan Winston, Brian Gazzard, et al.. (2013). Week 96 renal safety update of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF from two phase 3 randomized controlled trials. Journal of the International AIDS Society. 16(Suppl 1). 1 indexed citations

17.

Bruce, R. Douglas, Peter Winkle, Joseph M. Custodio, et al.. (2013). The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(4). 480–484. 14 indexed citations

18.

Elion, Richard, Jean‐Michel Molina, José Ramón Arribas, et al.. (2013). A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(4). 494–497. 33 indexed citations

19.

Ruane, Peter, Edwin DeJesus, Daniel Berger, et al.. (2013). Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(4). 449–455. 247 indexed citations

20.

Rhee, Martin S., Christopher H. Schmid, Lesley A. Stevens, & Janet Forrester. (2008). Risk Factors for Proteinuria in HIV-Infected and -Uninfected Hispanic Drug Users. American Journal of Kidney Diseases. 52(4). 683–690. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact